MedTrace Logo

Open-label Extension Study of GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)

NCT04816604 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2026-04-09

No results posted yet for this study

Summary

This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.

Conditions

Interventions

DRUG

GB002 (seralutinib)

Capsule containing GB002 (seralutinib)

DEVICE

Generic Dry Powder Inhaler

Generic dry powder inhaler for GB002 (seralutinib) delivery

Sponsors & Collaborators

  • GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Richard Aranda · Gossamer Bio Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-05
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States
  • Australia
  • Czechia
  • France
  • Germany
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04816604 on ClinicalTrials.gov